In vitro inhibition of human small intestinal and liver microsomal astemizole O -demethylation: different contribution of CYP2J2 in the small intestine and liver

References

• HASHIZUME, T., IMAOKA, S., MISE, M., TERAUCHI, Y., FUJI', T., MIYAZAKI, H., KAMATAKI, T. and FUNAE, Y., 2002, Involvement of CYP2J2 and CYP4F12 in the Metabolism of ebastine in human intestinal microsomes. Journal of Pharmacological and Experimental Therapeutics, 300, 298–304.
   Google Scholar
• HASHIZUME, T., MISE, M., TERAUCHI, Y., LUAN, O., FUJI', T., MIYAZAKI, H. and INABA, T., 1998, N-dealkylation and hydroxylation of ebastine by human liver cytochrome P450. Drug Metabolism and Disposition, 26, 566–571.
   Google Scholar
• HEYKANTS, J., VAN PEER, A., WOESTENBORGHS, R., JAGENEAU, A. and VANDEN, B., 1986, Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man. Drug Development Research, 8, 71–78.
   Web of Science ®Google Scholar
• JONES, B. C., HYLAND, R., ACKLAND, M., TYMAN, C. A. and SMITH, D. A., 1998, Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metabolism and Disposition, 26, 875–882.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., CHIBA, M. and BAILLIE, T. A., 1999, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacological Review, 51, 135–158.
   Google Scholar
• MATSUMOTO, S., HIRAMA, T., MATSUBARA, T., NAGATA, K. and YAMAZOE, Y., 2002, Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metabolism and Disposition, 30, 1240–1245.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO, S. and YAMAZOE, Y., 2001, Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. British Journal of Clinical Pharmacology, 50, 1–11.
   Google Scholar
• MEULDERMANS, W., HENDRICKX, J., LAUWERS, W., HURKMANS, R., SWYSEN, E. and HEYKANTS, J., 1986, Excretion and biotransformation of astemizole in rats, guinea-pigs, dogs, and man. Drug Development Research, 8, 37–51.
   Web of Science ®Google Scholar
• NAKAMURA, T., OKADA, K., NAGATA, K. and YAMAZOE, Y., 2000, Intestinal cytochrome P450 and response to rifampicin in rabbits. Japanese Journal of Pharmacology, 82, 232–239.
   PubMedGoogle Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOU, T., GONZALEZ, F. J. and TSUTSUI, M., 1996, Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• RICHARDS, D. M., BROGDEN, R. N., HEEL, R. C., SPEIGHT, T. M. and AVERY, G. S., 1984, Astemizole, a review of its pharmacodynamic properties and therapeutic efficacy. Drugs, 28, 38–61.
   PubMed Web of Science ®Google Scholar
• SCARBOROUGH, P. E., MA, J., Qu, W. and ZELDIN, D. C., 1999, P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metabolism Review, 31, 205–234.
   PubMed Web of Science ®Google Scholar
• TAAVITSAINEN, P., JUVONEN, R. and PELKONEN, O., 2001, In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metabolism and Disposition 29, 217–222.
   PubMed Web of Science ®Google Scholar
• THUMMEL, E. K., KUNZE, L. K. and SHEN, D. D., 1997, Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Advanced Drug Delivery Review, 27, 99–127.
   PubMed Web of Science ®Google Scholar
• TORCHIN, C. D., MCNEILLY, P. J., KAPETANOVIC, I. M., STRONG, J. M. and KUPFERBERG, H. J., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes. Drug Metabolism and Disposition, 24, 1002–1008.
   PubMed Web of Science ®Google Scholar
• Wu, S., MOOMAW, C. R., TOMER, K. B., FALCK, J. R. and ZELDIN, D. C., 1996, Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. Journal of Biological Chemistry, 271, 3460–3468.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI, T., HASHIZUME, T., MATSUDA, M., SAKASHITA, M., FUJII, T., SEKINE, Y., NAKASHIMA, M. and UEMATSU, T., 1994, Pharmacokinetics of the H1 -receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung, 44, 59–64.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., SUZUKI, M., TANE, K., SHIMADA, N., NAKAJIMA, M. and YOKOI, T., 2000, In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone. Xenobiotica, 1, 61–70.
   Google Scholar
• ZELDIN, D. C., FOLEY, J., GOLDSWORTHY, S. M., COOK, M. E., BOYLE, J. E., MA, J., MOOMAW, C. R., TOMER, K. B., STEENBERGEN, C. and Wu, S., 1997, CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Molecular Pharmacology, 51, 931–943.
   PubMed Web of Science ®Google Scholar
• ZELDIN, D. C., FOLEY, J., MA, J., BOYLE, J. E., PASCUAL, J. M., MOOMAW, C. R., TOMER, K. B., STEENBERGEN, C. and Wu, S., 1996, CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Molecular Pharmacology, 50, 1111–1117.
   PubMed Web of Science ®Google Scholar
• ZHANG, W., KILICARSLAN, T., TYNDALE, R. F. and SELLERS, E. M., 2001, Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition, 29, 897–902.
   PubMed Web of Science ®Google Scholar